Clueda AG, a spin-off from the Helmholtz Zentrum München, develops software solutions for big data analysis based on artificial neural networks. Unique algorithms not only gather vast amounts of data from varied sources, but also structure and evaluate them in a similar way to the human brain. ‘The approach appealed to us right from the…
As ‘Best of X’ partner, Ascenion has now nominated a spin-off project and a start-up for the start-up pitch competition in Hamburg on 13 July 2015: Cardior Pharmaceuticals and i3 membrane GmbH. Cardior Pharmaceuticals is a spin-off project from Hannover Medical School, led by Prof. Thomas Thum, one of the world’s most renowned cardiologists and…
OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has attracted Dr Ulrich Dauer as Chief Executive Officer. With twenty years of professional experience and a proven track record in the life-science industry, he brings additional leadership expertise to the team. Prior to joining OMEICOS, Ulrich Dauer was…
US-based Spero Therapeutics LLC closed a $30 million Series A financing round led by Lundbeckfond Ventures. Further new investors are Merck Research Ventures and The Kraft Group. All existing investors participated as well. The company will use the proceeds to advance its pipeline of novel treatments against severe bacterial infections, including…
A good year ago, Medigene acquired Trianta, a spin-off from the Helmholtz Zentrum München, taking on not only three innovative platforms for the development of anti-cancer immunotherapies, but also Prof. Dolores Schendel and her entire team. Since then, the most advanced platform, a personalized dendritic cell vaccine, has made significant…
Ascenion is supporting the start-up event ‘Best of X’ as nominating partner. ‘Best of X’ is a not-for-profit initiative that brings together players from regional start-up scenes for at least one evening: entrepreneurs, universities, research institutes, network institutions, venture capitalists and business angels. The competition offers…
Berlin, Germany, 15 April 2015 - OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius…
Dualis Medtech GmbH, a spin-out from the German Aerospace Center, and ReliantHeart, Inc. will work together to implement a wireless energy transfer system for ReliantHeart’s HeartAssist5® ventricular assist device. The resulting system is intended for critically ill heart patients, whose heart can no longer pump enough blood to sustain the body.…
Mediated by Ascenion, the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC) have closed a collaboration agreement for the discovery of new anti-infectives against methicillin-resistant Staphylococcus aureus (MRSA), a multi-drug resistant pathogen. MRSA causes an estimated number of 14,000 hospital infections…
At the end of last year, Baxter International Inc. announced that the company has submitted a biologics license application to the United States (US) Food and Drug Administration (FDA) for the approval of BAX111, a recombinant von Willebrand factor (rVWF) in development for the treatment of patients with von Willebrand disease, the most common…
As a partner of the ASTP-Proton Conference, Ascenion is pleased to invite you to Istanbul from 20 - 22 May 2015.The annual conference is one of the biggest conferences for knowledge and technology transfer professionals in Europe.
‘I’m very much looking forward to discussing key challenges and creating new ideas for taking an increasingly…
Prof. Klaus Brandenburg’s start-up, Brandenburg Antiinfektiva GmbH, has been selected by the Leibniz Association as one of the two first recipients of the ‘Leibniz-Gründerpreis’, worth EUR 50,000. The award was initiated last year to highlight entrepreneurial projects with strong commercial and social impact and to support their development before…
Over 400 entrepreneurs, clinicians, top-notch researchers, investors, policy makers, and senior executives in the healthcare industry will once again meet in Berlin to discuss the latest innovations during the 8th Charité Entrepreneurship Summit. This high-value, global network will offer exclusive access to key decision makers who influence the…
BioVaria is designed for dealmakers and investors from the global life-science sector responsible for identifying, licensing or funding break-through innovations. In just one interactive day it showcases around 50 licensable life-science technologies originating from publicly funded research as well as some of Europe’s most promising spin-offs.…
Spend two days in serious, open, interactive round-table discussions with your peers from Europe’s leading biotech and life sciences tech transfer offices (TTOs), and build real business relationships and collaborations with potential industry partners and VC, corporate and royalty investors from across Europe.
Ascenion has long been a…
5 March 2015, Munich – Ascenion, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has negotiated a licence agreement providing US-based Spero Therapeutics with exclusive rights to develop and commercialize a series of novel anti-infective compounds discovered at the Helmholtz Institute for Pharmaceutical…
Latest findings and developments in the life sciences and their implementation in innovative technologies and new products in areas such as pharmaceutics, food and biotechnology will be at the focus of the 9th International Congress 'Forum Life Science'.
In the parallel sessions of "Pharma Development", "Food & Nutrition"…
